Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?

To: Lee Fredrickson who wrote (257)	5/6/1998 3:39:00 PM
From: john jansen	Respond to of 705

Keep in mind that u will need to buy stock at 200 to 300/share when phase 3 starts

To: Lee Fredrickson who wrote (257)	5/7/1998 1:22:00 PM
From: Marty	Respond to of 705

Lee, I appreciate your point and the last thing I would wish on anyone, most particularly a company whose stock I own for over a year now, would be the legal Hell you described. I know they have to watch what they say but, in my view, they take it too far. They say that those who have been bitten by alligators are afraid of lizards. The point is that they could, for example, publish (send to the press) the reports and presentations they already have, they have to write them (or describe them) so they are less technical and more understandable to the public, they could share the status of the tests ... that they are now testing so many people in so many test sites, they could describe the nature and size of the problem, they could say what is going on now and what's next, and on and on. There are so many articles being written lately in the lay journals about promising approaches .... NOTHING is mentioned as far as I can tell, about NEOT ... either in the AZ or the spinal cord injury area. What's happening with the spinal cord injury drug testing? Isn't there a connection with what NEOT is testing and a potential treatment for Christopher Reed's injury? Aren't public relations firms SUPPOSED to relate to the public? NOBODY is asking for hype but, as I have written before this is like pushing a string. And, again as I have written before, when something does come out it is like getting cotton candy when you are really hungry for a steak. I submit that they have to be more sensitive to the legitimate needs of their shareholders. I, for one, have an emotional as well as financial investment in the company. I know that is wrong for an investor but the promise of the whole thing just overwhelms me.

To: Lee Fredrickson who wrote (257)	5/7/1998 7:13:00 PM
From: David M. Evans	Read Replies (2) \| Respond to of 705

You have summed up the feelings of the management in a nutshell, I suspect. As I have said on many previous occasions, I would prefer a company that is short on hype and long on science, rather than the reverse <g> Yes, it would be nice if the stock was worth more, but then I'd also like to be taller and better looking ... There is a very good piece on NEOT in this month's NeuroInvestment newsletter. The author ventured in here some time ago, and was given short shrift for not hyping the stock, as we would expect him to do ... Actually, he was spot on in his last assessment that at $16 odd bucks, NEOT had gotten a little ahead of itself. I suspect that he's also fairly objective in his current assessment that the stock will be at $14 by year end, albeit a trifle conservative (that sounds like a political pudding?) My guess is that it will be nearer $20 by year end, and I shall be the same height and no better looking.